Pharmaceutical News

RSS

International study evaluates new class of drugs for treating primary biliary cirrhosis

Results of a study presented today at the at the International Liver CongressTM 2010 reveals the effects of a new drug for the treatment of primary biliary cirrhosis, and shows further evaluation is necessary.

16 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

TruthAboutGardasil.org: Governments need to suspend HPV vaccinations/programs

The global outrage at reports of injustices inflicted on the children of India from unethical trials and experimentation of HPV vaccines in socially disadvantaged groups extends to women and children worldwide subjected to similar violations.

16 Apr 2010

Pharmacyclics to present on Btk and HDAC programs at AACR 2010

Pharmacyclics, Inc. today announced multiple presentations covering its Btk and HDAC programs at the American Association for Cancer Research 2010 Annual Meeting being held April 17-21 in Washington, DC.

16 Apr 2010

Investment report on Anadys Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Anadys Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

16 Apr 2010

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics.

16 Apr 2010

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the Company's New Drug Application (NDA) for the use of Soliris® (eculizumab) as a treatment for patients in Japan with paroxysmal nocturnal hemoglobinuria (PNH).

16 Apr 2010

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from several studies demonstrating that laquinimod, a novel, investigational once-daily oral immunomodulator for relapsing remitting multiple sclerosis (RRMS) may have neuroprotective properties in addition to its anti-inflammatory effects.

16 Apr 2010

Revlimid now available to multiple myeloma patients in Nova Scotia

Following the broadcast on CTV's W5 of the plight of multiple myeloma patient Frank Boyd and his inability to obtain appropriate drug treatment, on March 27, the President of Myeloma Canada, John Lemieux, immediately wrote to the Honourable Maureen MacDonald, Minister of Health of Nova Scotia urging her to implement an interim arrangement to ensure that Revlimid is available to multiple myeloma patients, including Mr. Boyd, in Nova Scotia.

16 Apr 2010

CombinatoRx's synergistic drug combinations for cancer treatment to be highlighted at AACR 2010

CombinatoRx, Incorporated today announced that preclinical data on its discovery of novel synergistic drug combinations for the treatment of cancer will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

16 Apr 2010

Self-monitoring of Coumadin levels reduces risk of blood clots by 50%: Study

A new review of existing research finds that many patients who take an anti-clotting drug or "blood-thinner" can benefit from monitoring the levels of the drug themselves instead of going to clinics for blood tests.

16 Apr 2010

Drugstores try to increase their presence with in-store clinic market

Drugstores are trying to bolster their presence in the in-store clinic market, even though the concept has thus far not been a particularly profitable one.

16 Apr 2010

FDA approves Akorn's ANDA for generic version of Dilaudid-HP Injection

Akorn, Inc. a niche generic pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted approval of the Company's Abbreviated New Drug Application for the generic version of Dilaudid-HP® 10mg/ml Injection. The company intends to begin shipping the product next month.

16 Apr 2010

Watson Laboratories' ANDA for generic Toprol XL tablets receives FDA approval

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for metoprolol succinate extended-release tablets USP in the 100 and 200 mg strengths, the generic equivalent to AstraZeneca's Toprol XL® tablets.

16 Apr 2010

3M Drug Delivery Systems grows its product portfolio in Asia’s pharmaceutical industry

3M Drug Delivery Systems recently advanced its participation in the Asian market with a sponsorship of the Asia Pharma R&D Leaders 2010 event, held March 4 and 5 in Shanghai, China.

16 Apr 2010

Consortium studies gene-drug relationship to determine optimal warfarin doses

If Julie Johnson had her way, doctors would check a patient's genes before writing a prescription. Everyone responds differently to medicines—one that works for you might not work for me, or it could even be harmful. These individual responses depend to an extent on our genetic make-up.

16 Apr 2010

Contura submits PMA for Aquamid

Contura Inc. has submitted a Premarket Approval Application for Aquamid to the U.S. Food and Drug Administration requesting marketing approval in the U.S. for the aesthetic treatment of moderate to severe facial wrinkles and folds.

16 Apr 2010

Smith & Nephew to launch new line extensions to ACTICOAT antimicrobial barrier dressing portfolio

The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc will launch extensions to its ACTICOAT(TM) Silver Coated Antimicrobial Barrier Dressing portfolio at the upcoming Symposium on Advanced Wound Care Spring meeting April 17-19, 2010, in Orlando, FL. The new dressings will be highlighted at the Smith & Nephew booth, #301.

15 Apr 2010

Study: Atorvastatin may slow down MS progression

A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.

15 Apr 2010

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Cumberland Pharmaceuticals Inc. today announced results from a meta-analysis comparing the efficacy and safety of ibuprofen and acetaminophen, which was published in the March edition of the peer-reviewed journal The Annals of Pharmacotherapy. The publication notes that in a majority of evaluated studies ibuprofen demonstrated superior efficacy compared to acetaminophen for the treatment of pain and fever, and found no significant safety differences between the drugs.

15 Apr 2010

Pharmaceutical News

International study evaluates new class of drugs for treating primary biliary cirrhosis

Results of study comparing REMICADE to azathioprine for Crohn's disease published

TruthAboutGardasil.org: Governments need to suspend HPV vaccinations/programs

Pharmacyclics to present on Btk and HDAC programs at AACR 2010

Investment report on Anadys Pharmaceuticals

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Revlimid now available to multiple myeloma patients in Nova Scotia

CombinatoRx's synergistic drug combinations for cancer treatment to be highlighted at AACR 2010

Self-monitoring of Coumadin levels reduces risk of blood clots by 50%: Study

Drugstores try to increase their presence with in-store clinic market

FDA approves Akorn's ANDA for generic version of Dilaudid-HP Injection

Watson Laboratories' ANDA for generic Toprol XL tablets receives FDA approval

3M Drug Delivery Systems grows its product portfolio in Asia’s pharmaceutical industry

Consortium studies gene-drug relationship to determine optimal warfarin doses

Contura submits PMA for Aquamid

Smith & Nephew to launch new line extensions to ACTICOAT antimicrobial barrier dressing portfolio

Study: Atorvastatin may slow down MS progression

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News